OBiO Tech(SH:688238)2025-01-16 09:13Revenue Projections - The company expects 2024 annual revenue to be between 236 million and 262 million CNY, an increase of 31.2 million to 57.2 million CNY compared to the previous year, representing a growth of 15.23% to 27.93%[3]. - In 2023, the company reported a revenue of 204.8 million CNY and a net loss of 127.9 million CNY[5]. Net Loss Projections - The projected net loss attributable to shareholders for 2024 is between 339 million and 282 million CNY, an increase in loss of 154.1 million to 211.1 million CNY compared to the previous year[4]. - The projected net loss attributable to shareholders, excluding non-recurring gains and losses, is expected to be between 352 million and 292 million CNY, an increase in loss of 158.5 million to 218.5 million CNY compared to the previous year[4]. Business Operations and Strategy - The company is focusing on expanding its CDMO business and has relocated operations to the Lingang Industrial Base, which has resulted in asset disposal losses and increased project transfer costs[6]. - The company is experiencing a decline in gross profit and net profit in its CDMO business due to historical low order prices and increased operational costs[6]. - The company emphasizes a "customer first" approach and aims to maintain stable growth in its cell and gene therapy CRO business[6]. Financial Caution - The financial data provided is preliminary and has not been audited by a registered accountant, and investors are advised to be cautious[8].